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Abstract 
Background: Pain in cancer patients is recognised as a major health problem yet few 
studies of both inpatient and outpatient populations have been carried out.   
Objective: To assess the frequency, type, and characteristics of pain in adult cancer 
patients, including both inpatients and outpatients.  
Design and setting: Cross-sectional study of 1,064 adult cancer patients (437 
outpatients and 627 inpatients) from 44 hospitals and/or long-term-care centres in 
Catalonia, Spain. Cancer patients suffering from pain of any aetiology for ≥ 2 weeks 
and/or under analgesic treatment ≥ 2 weeks were enrolled.  
Measurements: Demographic and pain data were collected. The Spanish version of the 
Brief Pain Inventory was used to assess pain.  
Results: Pain frequency was 55.3%.Pain was less frequent in outpatients than inpatients 
(41.6% vs. 64.7%; p < 0.001), although median pain duration was longer in outpatients 
(20 vs. 6 weeks; p < 0.001). Pain was assessable in 333 patients, and intensity was 
similar in both out- and in-patients ; however, outpatients reported less improvement, 
less pain interference with daily life, and less pain related to the cancer per se. In both 
groups, patients with multiple myeloma (73%), breast (65%), and lung cancer (61%) 
were most likely to report pain. 
Conclusions: Pain in cancer patients, both ambulatory and hospitalised, remains a 
challenge for health-care professionals, health administrators, and stakeholders. Our 
study reveals the high level of pain and distress that cancer patients continue to suffer, a 
problem that is particularly notable in outpatients due to the intensity and duration of 
the pain.   
Key words: pain, neoplasm, palliative care, prevalence 
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Introduction 
Cancer patients suffer from a wide variety of different pain syndromes
1
, most of 
which are related to metastatic spread or health status.
2 
 Multiple concurrent factors can 
cause pain, leading to pain syndromes that are usually chronic and can last for months, 
years, or even for the patient’s entire life.  Cancer encompasses a wide spectrum of 
tumours (both solid and haematological) and the pain associated with many of these 
cancers negatively affects both performance status and mood.
3.4
 
Pain in cancer patients has been recognised as a major health problem that 
impacts both quality of life and health care provision. Many studies have assessed the 
prevalence and impact of pain in different cancer patient populations, 
5.6.7
 although 
relatively few studies have been carried out in Southern Europe. 
8.9.10.11.12
 In Spain, 
although several epidemiological studies have been conducted to assess particular 
aspects of pain (e.g., breakthrough pain
13 
or neuropathic pain
14
), to our knowledge, no 
comprehensive pain studies (whether national or regional) have been carried out in a 
cancer patient population. Moreover, data is lacking   on differences in pain between 
adult cancer outpatients and inpatients. 
This knowledge gap, together with the need to better understand pain in cancer 
patients in our context, led us to design and carry out the comprehensive 
epidemiological pain study presented here. The aim of the study was to assess the 
frequency, type, and characteristics of pain in adult cancer patients, including both 
inpatients and outpatients.  
 
Material and Methods 
This cross-sectional study enrolled a sample of ambulatory and hospitalised 
cancer patients ≥18 years of age with a histological diagnosis of solid or haematological 
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neoplasms. All recruited patients were in treatment at the oncology and/or palliative 
care (PC) service of acute care hospitals in Catalonia, or at a long-term-care (LTC) 
centre with dedicated PC resources, all of which are form part of the public, universally-
accessible National Health System of Catalonia, Spain.  
To obtain a representative sample of patients, we estimated that patients from 44 
hospitals and LTCs were needed. According to the Catalonian Healthcare Services 2002 
Directory, these 44 centres provided coverage for >80% of cancer patients in the region. 
Assuming a cancer pain frequency of 50%, with a 5% absolute precision and 95% 
confidence interval (95%CI), statistical calculations indicated that a minimum of 624 
inpatients and 435 outpatients would be needed to estimate the pain frequency in both 
populations. Since outpatient clinics are mostly tumour-type specific, the outpatient 
sample was restricted to the eight most common neoplasms (colorectal, lung, breast, 
prostate, bladder, leukaemia, non-Hodgkin's lymphoma, and multiple myeloma) to 
avoid potential bias in pain frequency related to over- or under-representation of 
particular tumour types. The number of cases needed for each of these tumour types was 
calculated according to the incidence rate in our region
15
. Hence, each hospital (based 
on the estimated tumour incidence) was expected to enrol a specific number of patients 
of each tumour type. Finally, patients were randomised for enrolment according to the 
weekly list of patient consultations.  
The study was approved by the ethics committees of all participating centres. All 
patients signed informed consent forms. The participating hospitals and the local 
investigators are listed in the Appendix.  
Patients were screened between January 2009 and December 2010, inclusive.  
The clinical records of a randomized group of patients were reviewed by a specially-
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trained health-care professional interviewer (doctor or nurse)—assisted, in most cases, 
by the patient's treating physician—to identify the patients with pain.  
Patients were considered to have pain if they reported any pain (regardless of 
aetiology) and/or the medical records showed that the patient was under analgesic 
treatment lasting ≥2 weeks. Patients with pain were invited to participate and asked to 
sign the informed consent form.  
Cognitive status was checked by the Spanish version of the Mini-Mental Status 
Examination (MMSE) before the pain assessment
16
. Patients with cognitive failure were 
excluded from further assessment in this study.  
Given the inherent differences between inpatients and outpatients (different 
patient profiles, treatment regimens, and schedules), two distinct groups were 
considered: inpatient sampling was performed randomly whereas outpatients were 
stratified by tumour type. Demographic, clinical and pain variables collected are shown 
in Table 1.  
 
Statistical analyses:  
Categorical variables are shown as percentages with 95% CIs. Continuous 
variables are presented as means and standard deviations (SD) or as medians and 
interquartile range. Categorical data were compared using Pearson's χ
2
 and Fisher's 
exact test, while the linear-by-linear χ
2
 test was used for trends. Continuous variables 
were compared using the Student's t-test or Mann-Whitney tests depending on the 
distribution (normal or non-normal). A value of p<0.05 was considered statistically 
significant. All analyses were performed with the SPSS package (v. 13 for Windows). 
 
Results 
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Of the 1064 patients initially screened, 588 (55.3%) met the study criteria for 
pain, with a significantly lower percentage of outpatients vs. inpatients meeting these 
criteria(41.6% vs. 64.7%; p < 0.001). Of the 588 patients, 373 provided informed 
consent and 333 of these were cognitively intact and, therefore, eligible for pain 
assessment (Figure 1).  
As shown in Table 2, patients in LTCs reported significantly more pain than 
those in acute hospitals. Similarly, patients under PC care reported more pain than those 
in Medical/Radiation Oncology, and Haematology services. Pain was more frequent in 
women. No significant differences in pain were observed by age.  Pain frequency 
increased significantly in relation to Karnofsky score (KPS) decline and cancer spread 
in both solid and haematological malignancies. We observed no significant association 
between pain frequency and time-elapsed since cancer diagnosis. Pain was more 
common in patients being treated with radiotherapy and less frequent in those receiving 
chemotherapy. The tumour types (in both inpatients and outpatients) with the highest 
percentage of patients with pain were multiple myeloma (73%), breast cancer (65%), 
and lung cancer (61%). In contrast, tumours with the lowest pain frequency were 
lymphoma (40%) and leukaemia (25%) (data not shown). 
When comparing the 333 patients assessable for pain by place of assessment 
(Table 3), we found that ambulatory patients had a significantly better performance 
status, less advanced disease, longer time with cancer, and longer duration of pain than 
inpatients. Notwithstanding these findings, no significant differences in pain intensity, 
assessed according to average and worst pain, were observed.  
Mean pain intensity and interference are shown in Table 4.  Even though mean 
pain interference was lower in outpatients than inpatients, there were no significant 
between-group differences in pain intensity. On the whole, men experienced more pain 
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interference in their ‘relations with others’ and more pain interference with ‘sleep’ than 
women (data not shown). No differences were found on other pain dimensions. Patients 
with a KPS ≤50 reported significantly more pain interference than those with KPS >50. 
Patients with metastatic disease also presented significantly more pain interference than 
those without metastasis. All Brief Pain Inventory (BPI) interference dimensions were 
more significantly affected in patients with KPS ≤50, and in patients with metastases.  
Table 5 shows the main pain types  (and their pathophysiology). No statistically 
significant between-group differences (gender, age, KPS, time-from-cancer diagnosis 
and cancer stage) were observed in terms of the pain types and probable 
pathophysiological mechanisms.  
The percentage of patients with tumour-related pain was significantly higher in 
the inpatient group vs. outpatients (81.3% vs. 50.4%; p < 0.001) (data not shown). 
Conversely, outpatients reported higher levels of pain unrelated to the tumour or the 
anti-tumour treatment. Moreover, in patients with metastatic disease, tumour-related 
pain was significantly greater than in patients with no evidence of cancer or loco-
regional spread of the disease; 80% vs. 49.6% p < 0.001, respectively. 
 
Discussion 
The present study evaluated the largest sample to date of an unselected 
population of both ambulatory and hospitalised cancer patients in Southern Europe 
suffering from pain. To our knowledge, it is the first such study carried out in Spain. 
The findings confirm that the pain frequency in our region (55.3%) is in-line with rates 
reported in other countries
10, 22, 23, 24, 25,26
. This result is also consistent with those from a 
large meta-analysis of 52 studies, which reported an overall pain prevalence of 53%
24
.  
In addition, our data agree with previous reports indicating that pain frequency was 
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higher in patients with poor functional status
10
 and in patient with advanced disease. 
Taken together, the data suggest that, on average, half of all cancer patients will 
experience pain.  
Some authors
27
 have suggested that the percentage of patients reporting severe 
pain (NRS ≥7) in the ‘average’ and ‘worst pain’ categories could be used as an indirect 
indicator of poor pain control.
  
In our sample, these percentages were 13.2% and 61.6%, 
respectively, without significant differences between in- and out-patients. Caraceni et 
al
2
 reported similar findings. In their study, those authors found 20% had severe 
‘average pain’ while 67% presented severe ‘worst pain’. It appears that these 
percentages have not changed substantially in the time that has passed since Caraceni et 
al. published their report, eleven years ago. Consequently, this suggests that pain in 
cancer patients may not have improved as much in Europe and in Spain as some authors 
have claimed.
5,28
  
In our study, the prevalence of moderate-severe pain (NRS >5) was 31.5% 
which is in agreement with authors who have reported a range from 20-45%.
22,23,24,29,30
  
In most studies, the mean pain duration ranges from 6 months to 1 year.
2, 18
 
Interestingly, inpatients had a shorter median pain duration (6 weeks) than outpatients 
(20 weeks); however, the period of pain was protracted in both groups, and this is 
indicative of the amount of pain that patients in our study sample had to tolerate.  
With regard to patients’ reported pain relief, the mean improvement was slightly 
more than 61%, similar to the pain improvement (65%-68%) found in other studies.
3,31  
Pain interference in our sample was similar to the rates reported by Daut
3
 and 
Strassels.
32
 Of note is that both inpatients and outpatients in our study reported similar 
rates of mean ‘average’ pain; however, outpatients reported significantly less pain 
interference and pain relief. It is not clear if this finding represents  an adverse impact 
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(or dissatisfaction) associated with extended periods of pain, although pain intensity has 
been recognised as the major predictor of pain interference with daily-life activities
3
. 
Nevertheless, it is well-known that the reported intensity varies in response to factors 
such as the meaning of pain,
3,33 
breakthrough pain,
34 
psychological distress,
35 
and pain 
education.
36 
Although  several studies have described multiple reasons underlying 
inadequate cancer pain management in outpatients,
37,38,39 
 those same studies have also 
indicated that this is a complex, multi-factorial problem. In the present study, we too 
found it difficult to pinpoint the reasons for poor pain alleviation in our outpatient 
group. For this reason, it is evident that further research into this complex topic is 
warranted; however, it is important physicians, nurses, and health authorities be aware 
of the existence of this issue.  
We found that, compared to men, a significantly higher proportion of women 
reported pain. A recent review concluded that women appear to have lower pain 
thresholds, greater ability to discriminate painful sensations, higher pain ratings, and 
lower tolerance of pain.
40
 As in other studies, we did not observe differences in pain 
prevalence in relation to age.
22,23,24  
In our study, the proportion of patients on chemotherapy who reported pain was 
lower than those not receiving chemotherapy, regardless of cancer stage. This finding 
should not be interpreted as cause and effect, since many confounders can be involved 
and because this was an incidental finding of the present study, it is difficult to 
determine the reasons for this difference. To date, very few studies have assessed the 
potential analgesic role of chemotherapy, and further research is needed.
41,42,43  
It is 
well-known that  pain prevalence is higher in patients receiving radiotherapy vs. those 
without radiotherapy
43
 and our findings confirm this. However, as other authors have 
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noted, this higher prevalence may be due to the preference to use radiotherapy for pain 
palliation.  
We found that nearly 70% of pain was directly related to the cancer itself. 
Hospitalised patients were more affected by cancer-related pain than outpatients, a 
finding that is consistent with other reports.
10,31
 However, these findings must be 
contextualised, as differences in patient characteristics between different studies can 
impact the results: in our study sample, only about 50% of patients had metastatic 
disease vs. 70% in the study by Caraceni et al
2
.  
Anti-tumour treatment is another source of pain in cancer patients. Previous 
estimations have suggested that treatment-related pain accounts for 17-20% of pain
2, 3, 
44
.  We found, in contrast,  that treatment-related pain accounted for only 6.6% of all 
pains in our sample. Conversely, for non-cancer related pain, we found that nearly 20% 
of all pains were due to this pain type, a finding that contradicts other studies 
2, 3 
in 
which non-cancer related pain ranged from 2.3-9%. The reason for this divergence is 
not clear, although it could be due to the bias in better KPS in ambulatory patients 
(median KPS of 80%), 11.9% of whom were cancer-free. Nevertheless, outpatients in 
our sample experienced significantly more treatment-related pain (and the sequelae 
thereof) compared to inpatients, in addition to more pain unrelated to the disease or its 
treatment.  However, it is important to note that non-cancer related pains can be just as 
intense as cancer-related pains and can have an equal or even greater interference on 
daily-life activities, depending on the nature of the pain.
3
  
In our study, around 40% of patients experienced pain of mixed origin, a 
percentage that is similar to the 43% reported in other studies.
2
 Neuropathic pain was 
less common in our study (5.2%) compared to the Caraceni et al
2
 study (7.7%). If 
overall pain with neuropathic component is pooled, the frequency of neuropathic pain 
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rises to 30% in our study, similar to the figure reported in a recent multi-centre study 
(33%).
14
 
Limitations worth noting. First, patients were considered to have prolonged 
pain—and this was an inclusion criterion—when the pain lasted for ≥ 2 weeks or the 
patient was under analgesic treatment ≥2 weeks. This cut-off point could be 
controversial because, according to the International Association for the Study of Pain 
(IASP) 
45
, chronic pain in non-malignant conditions is defined as pain lasting 3 or more 
months. However, as that same report notes, a 3 month cut-off value is excessive in 
cancer patients, many of whom may have a life-expectancy that is shorter than this 
period. As a result, we believe the cut-off point should be adjusted by clinical 
experience. In our experience, a  2-week cut-off point allows us to rule out acute and 
transient pain conditions, and thus a pain duration ≥ 2 weeks seems appropriate to 
classify a pain as prolonged in this specific patient population. A second potential 
limitation of our study is the relatively low participation rate, which was approximately 
60% for the inpatient group. This was due to the fact that some patients simply did not 
wish to participate. However, other similar multi-centre studies present similar 
participation rates ranging from 51%
5
 to 66%.
22
 A third and final potential limitation is 
that our sample did not include all possible tumour types (notably head and neck 
cancers) in which pain is highly prevalent
46
.Neverthess, we did include the most 
common cancer types and although it would have been desirable to assess more cancers, 
doing so would have been impractical due to the large number of patients required and 
because the present study was not designed to assess the pain prevalence for each cancer 
type (even though the data obtained accurately characterises  pain prevalence in the 
study population. 
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CONCLUSION  
 The present study adds substantial new and comprehensive epidemiological 
information about the pain suffered by cancer patients in our country, both in- and 
outpatients. Although the importance of cancer pain relief has become more widely 
recognized, cancer-pain remains a major problem, despite the considerable efforts made 
by health-care providers in recent decades to improve pain alleviation. 
Our study reveals the high level of pain and distress that cancer patients in our 
region still suffer, a problem that is particularly concerning for outpatients due to the 
intensity and duration of the pain.  More efforts need to be made to increase awareness 
of this problem and to find better solutions. 
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J. Planas; Hospital de l’Esperança - Barcelona 
J. Planas; Hospital del Mar - Barcelona  
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M. Amor; Mutuam-CSS Eixample - Barcelona 
F. Lynn. Fundació Sociosanitària de Barcelona- L’Hospitalet de Llobregat  
P. Loncan, Residència Sta. Susana - Caldes de Montbui, Barcelona 
J. Casanovas; Hospital de Sant Jaume - Calella 
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M. Doménech; Centre Hospitalari Fundació ALTHAIA - Manresa 
M. Doménech; Hospital Sant Joan de Déu Fundació ALTHAIA-Manresa 
A. Verdaguer; Hospital de Mataró - Mataró 
R. Cristòfol. Antic Hospital de Sant Jaume i Santa Magdalena- Mataró 
J. Martí and I. Grimau; Corporació Sanitària Parc Taulí - Sabadell 
H. Camell. Hospital Residència Sant Camil-Sant Pere de Ribes. 
M. Esteva and F. Novell; Fundació Hospital de l’Esperit Sant-Sta Coloma de Granollers 
C. Sala; Hospital de Terrassa (Consorci Hopitalari de Terrassa), Terrassa 
M. Álvarez and V. Romaní; Hospital Mútua de Terrassa - Terrassa 
A. Albó; Hospital Sta Creu - Vic 
M. Nogué; Consorci Hospitalari de Vic - Vic 
M. González, J. Martínez and M. Pardo; Hospital Comarcal de l’Alt Penedés, 
Vilafranca del Penedés 
I. Matchengs; Hospital del Sagrat Cor - Barcelona 
Girona: 
A. Boixadera; CSS Bernat Jaume - Figueres 
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J. Pérez; Centre SAR Jaume Nadal - Lleida 
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M. Serrano, Hospital Sta Maria - Lleida 
M. Nabal; Hospital Universitari Arnau de Vilanova - Lleida 
Tarragona: 
D. Rodríguez; Hospital Universitari Sant Joan - Reus 
V. Valentí; Hospital de Sant Pau i Santa Tecla - Tarragona 
V. Santacruz; Hospital Verge de la Cinta - Tortosa 
V. Santacruz; Hospital de la Sta Creu - Tortosa 
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Table 1. Variables  
Type of variable 
 
Variable Options Definitions 
Demographic Data Type of institution  Acute hospital   
LTC 
 
Long-Term-Care 
Care service Medical Oncology 
Radiation Oncology, 
Clinical Haematology 
Palliative Care 
 
Age 20-45 years  
45-65 
66-85 
 >85 years  
Adults 
Middle-aged 
Aged 
Elderly. 
Gender Male / Female  
Performance status by 
Karnofsky Performance 
Score (KPS) 
  
Solid Tumour stage 
 
No evidence  
Local tumour 
Regional tumour 
Metastatic tumour 
 
 
Haematological neoplasms 
classifications  
Localized 
 
Leukaemia:  0 or 1  
(Rai scale17) 
Lymphoma: stages I-II  
(Ann Arbor Staging
18
) 
Multiple Myeloma:stages I-II 
(Durie-Salmon Staging
19
) 
 
Disseminated Leukaemia:  2 to 4 
(Rai scale
17
) 
Lymphoma: stages III-IV 
(Ann Arbor Staging
18
) 
Multiple Myeloma: stage III 
(Durie-Salmon Staging
19
) 
 
Anti-tumour treatment  Positive  
 
when administered ≤ 4 weeks 
prior to inclusion 
Negative when administered > 4 weeks 
prior to inclusion 
Pain Data Numbers of pains    Defined as the number of 
pain sites that the patient 
referred when asked 
Pain location    Defined as the pain site; in 
cases with multiple pain 
locations, the most painful 
pain site was selected. 
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Type of pain  
 
 Determined by the trained 
interviewer based on the 
patient’s description in 
conjunction with the clinical 
records or the diagnostic 
criteria of the treating 
physician. 
 
Pain intensity by BPI 
20
 
Numeric Rating Scale 
[NRS] 
  
Worst pain 
Best pain,  
Right-now pain 
Average pain 
no pain NRS=0 
21
 
mild pain NRS=1-4 
moderate pain NRS=5-6 
severe pain NRS=7-10 
 
Pain relief by BPI  NRS 0% to 100% 
Pain interference by BPI General activity; 
Mood; Walking 
ability; Working; 
Personal relations; 
Sleep; Enjoyment of 
life 
NRS 0 to 10 
BPI: Brief Pain Inventory; NRS: Numeric rating Scale   
Page 22 of 29
Mary Ann Liebert Inc, 140 Huguenot Street, New Rochelle, NY 10801
Journal of Palliative Medicine
3 
 
Table 2. Pain frequency by patient characteristics. 
  TOTAL N (%) 95%CI p-value 
Centre type  Acute hospital
a 903 461 (51.1%) 46.5- 55.6 <0.001 
 Long-term-care (LTC)a 161 127 (78.9%) 71.8- 86  
Hospital service / 
department 
Medical & 
RadiationOncology 
602 287 (47.7%) 41.9- 53.5 <0.001 
Haematology 148 53 (35.8%) 22.9 – 48.7  
 Palliative care 314 248 (79.0%) 73.9 – 84.1  
Gender Male 611 302 (49.4%) 43.8 – 55.1 <0.001 
 Female 453 286 (63.1%) 57.5 – 68.7  
Age groups 20-45 90 49 (54.4%) 40.5 – 68.4 0.549 
 46-65 381 210 (55.1%) 48.4 – 61.8  
 66-85 544 297 (54.6%) 48.4 – 60.3  
 >85 49 32 (65.3%) 48.8 – 81.8  
Karnofsky 
performance status 
10-20 63 55 (87.3%) 78.5 – 96.1 <0.001 
30-40 119 88 (73.9%) 65.0 – 83.0  
 50-60 247 170 (68.8%) 61.9 – 75.8  
 70-80 294 164 (55.8%) 48.2 – 63.4  
 90-100 341 111 (32.6%) 23.8 – 41.3  
Time-from-cancer 
diagnosis 
≤ 3 months 185 97 (52.4%) 42.5 – 62.4 0.601 
3-6 months 165 93 (56.4%) 46.3 – 66.4  
 6 months-1 year 164 93 (56.7%) 46.6 – 66.8  
 1-3 years 295 170 (57.6%) 50.2 – 65.1  
 3-5 years 103 41 (39.8%) 24.8 – 54.8  
 > 5 years 152 94 (61.8%) 52.0 – 71.7  
Cancer stage * No evidence 86 24 (27.9%) 10.0 – 45.9 <0.001 
 Loco-regional 340 166 (48.8%) 41.2 – 56.4  
 Metastatic 621 387 (62.3%) 57.5 – 67.1  
Anti-tumour Any  548 276 (50.4%) 44.5 – 56.3 0.001 
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treatment None 516 312 (60.5%) 55.0 – 65.9  
 No chemotherapy 655 392 (59.8%) 55.0 – 64.7 <0.001 
 Chemotherapy 409 196 (47.9%) 40.9 – 54.9  
 No radiotherapy 958 514 (53.7%) 49.3 – 58.0 0.001 
 Radiotherapy 106 74 (69.8%) 59.4 – 80.3  
TOTAL  1064 588 (55.3%) 51.2- 59.3  
*Missing 17 patients 
a)  Includes both admitted and ambulant patients  
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Table 3. Comparison of pain characteristics between inpatients and outpatients 
assessable for pain (n=333)  
Characteristics Total Inpatient Outpatient  
 N (%) N (%) N (%) p-value 
Patients 333 206 127  
Gender      
Male 117 (53.2) 112 (54.4) 65 (51.2) 0.574 
Female 156 (48.8) 94 (45.6) 62 (48.8)  
Age  (years) [Median (IQR)* 66 (55-74) 65 (54-73) 67(58-74) 0.158 
Karnofsky Performance Status 
(%)[Median (IQR)] 
70(50-90) 60 (50-80) 80(70-90) <0.001 
Cancer Stage     
No evidence 19 (5.7) 4 (2.0) 15 (11.9)  
 
<0.001 Loco-regional 96 (29.0) 55 (26.8) 41 (32.5) 
Metastatic 216 (65.3) 146 (71.2) 70 (55.6) 
Missing 2 patients     
Time from cancer diagnosis (days) 
[Median (IQR)] 
407 (146-966) 325 (109-759) 518 (194-1364) 0.001 
Pain Duration (weeks) 
[Median (IQR)] 
10 (4-24) 6 (4-16) 20 (8-96) <0.001 
No. of Pains [Median (IQR)] 1 (1-2) 1 (1-2) 1 (1-2) 0.392 
No. of pains  per patient     
1 pain  186 (55.9%) 119 (57.8%) 67 (52.8%) 
0.739 
2 pains  94 (28.2%) 56 (27.2%) 38 (29.9%) 
3 pains  41 (12.3%) 23 (11.2%) 18 (14.2%) 
≥ 4 pains 12 (3.6%) 8 (3.9%) 4 (3.1%) 
Pain site      
Abdomen 106 (32.3%) 76 (37.4%) 30 (24.0%) 0.032 
Extremities  85 (25.9%) 44 (21.7%) 41 (32.8%)  
Spinal column  55 (16.8%) 31  (15.3%) 24 (19.2%)  
Thorax 44 (13.4%) 25 (12.3%) 19 (15.2%)  
Page 25 of 29
Mary Ann Liebert Inc, 140 Huguenot Street, New Rochelle, NY 10801
Journal of Palliative Medicine
6 
 
Head & Neck 38 (11.6%) 27 (13.3%) 11 (8.8%)  
Missing: 5 patients     
Pain intensity     
Average pain     
None 48 (14.4%) 23 (11.2%) 25 (19.7%) 0.096 
Mild 148 (44.4%) 100 (48.5%) 48 (37.8%)  
Moderate 93 (27.9%) 55 (26.7%) 38 (29.9%)  
Severe 44 (13.2%) 28 (13.6%) 16 (12.6%)  
Worst pain     
None 23 (6.9%) 13 (6.3%) 10 (7.9%) 0.068 
Mild 54 (16.2%) 27 (13.1%) 27 (21.3%)  
Moderate 51 (15.3%) 28 (13.6%) 23 (18.1%)  
Severe 205 (61.6%) 138 (67.0%) 67 (52.8%)  
*IQR: Inter quartile range Q1-Q3  
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Table 4. Pain intensity and interference divided according to patient recruitment. 
 
 Total 
N = 333 
Inpatient 
N = 206 
Outpatient 
N = 127 
Difference 
95%CI 
P value 
 mean±SD mean±SD mean±SD   
Worst pain  6.7±3.0 7.0±2.9 6.2±3.0 0.2 - 1.5 0.012 
Best pain 1.6±2.1 1.6±2.1 1.6±2.3 -0.5 - 0.5 0.912 
Average pain 3.8±2.3 3.9±2.2 3.5±2.5 -0.1 - 0.9 0.121 
Right-now pain 2.4±2.5 2.4±2.5 2.3±2.5 -0.4 - 0.7 0.656 
Improvement (%) 61.3±32.5 66.8±30.9 52.3±34.7 7.1 – 21.9 <0.001 
General activity 4.2±3.9 5.0±3.9 2.8±3.3 1.4 - 3.1 <0.001 
Mood 4.2±3.9 5.4±3.9 3.3±3.6 1.3 - 2.9 <0.001 
Walking ability 4.3±4.1 4.8±4.2 3.4±3.6 0.5 – 2 <0.001 
Working 4.4±4.1 5.3±4.1 2.9±3.6 1.5 - 3.2 <0.001 
Personal relations 3.2±3.8 3.8±4.0 2.2±3.2 0.8 - 2.4 <0.001 
Sleep 3.3±3.7 3.8±3.9 2.3±3.4 0.6 - 2.3 <0.001 
Enjoyment of life 3.6±3.9 4.4±4.0 2.3±3.3 1.3 - 2.9 <0.001 
Σ interferences* 27.6±21.3 32.7±21.4 19.4±18.5 9.8 – 17.8 <0.001 
 
* Interference score results from summing the scores obtained for each pain interfered 
activity, ranging from 0 to 70. 
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Table 5. Types of pain and the associated pathophysiology  
Characteristics Total Inpatient Outpatient  
 N (%) N (%) N (%) p-value 
Patients 331 206 127  
Causes*      
Cancer involving bones and joints 66 (19.9) 46 (22.5) 20 (15.7)  
Cancer involving viscera 84 (25.4) 60 (29.4) 24 (18.9)  
Cancer involving soft tissues and miscellanea 49 (14.8) 38 (18.6) 11 (8.7)  
Cancer involving nerve structures 31 (9.4) 22 (10.8) 9 (7.1)  
Pain syndromes related with cancer treatment 22 (6.6) 7 (3.4) 15 (11.8)  
<0.001 
Pain unrelated to cancer and its treatment 65 (19.6) 22 (10.8) 43 (33.9) 
Unknown 14 (4.2) 9 (4.4) 5 (3.9)  
Pathophysiology **     
Somatic  109 (33.3) 57 (28.5) 52 (40.9)  
1.0000 
Visceral 64 (19.6) 46 (23) 18 (14.2) 
Neuropathic 17 (5.2) 14 (7) 3 (2.4)  
Somatic+visceral 47 (14.4) 30 (15) 17 (13.4)  
Somatic+neuropathic 54 (16.5) 28 (14) 26 (20.5)  
Visceral+neuropathic 9 (2.8) 6 (3) 3 (2.4)  
Somatic+visceral+neuropathic 19 (5.8) 13 (6.5) 6 (4.7)  
Unknown 8 (2.4) 6 (3) 2 (1.6)  
* Missing: 2 inpatients;  **Missing: 6 inpatients 
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Figure 1. Flow chart of patients through the study 
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Outpatient  
n=437 
Inpatient 
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Criteria: patient experienced pain and/or was under analgesic regime for more than 2 weeks 
Yes 
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(41.6%) 
Yes 
n=406 
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